Worth reading
78Important
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
1171000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Eighth series stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
Number of shares delivered during the month: 1,171,000 shares (1,171,000 new shares and 0 treasury shares transferred)
EVO FUND (issued on 12 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to exercise restrictions: 12.7% (1,171,000 delivered shares / 9,252,901 listed shares as of the payment date for the issue)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise prices in March 2026 were ¥620, ¥625, ¥628, ¥630, ¥632 and ¥678. Details of the adjustment clause and the floor price: Not disclosed
Number of Stock Acquisition Rights
Total issued: 85,000 stock acquisition rights. Unexercised as of the end of the month preceding the target month: 72,400; unexercised as of the end of the target month: 60,690
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Issued on 12 December 2025: Eighth Series of Stock Acquisition Rights with an exercise price adjustment clause, allocated to EVO FUND. Total issued: 85,000 stock acquisition rights. Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Eighth series stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 1,171,000 shares (1,171,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 12 December 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 12.7% (1,171,000 delivered shares / 9,252,901 listed shares as of the payment date for the issue) |
| Total number of issued shares | 10,512,901 shares (as of the end of the month preceding the target month, including 35,697 treasury shares) → Not disclosed |
| Exercise price | The exercise prices in March 2026 were ¥620, ¥625, ¥628, ¥630, ¥632 and ¥678. Details of the adjustment clause and the floor price: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 85,000 stock acquisition rights. Unexercised as of the end of the month preceding the target month: 72,400; unexercised as of the end of the target month: 60,690 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Issued on 12 December 2025: Eighth Series of Stock Acquisition Rights with an exercise price adjustment clause, allocated to EVO FUND. Total issued: 85,000 stock acquisition rights. Amount: Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of these stock acquisition rights in March 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.